IntraLase Corporation

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

IntraLase Corporation - overview

Established

1997

Location

Irvine, CA, US

Primary Industry

Medical Devices & Equipment

About

IntraLase Corporation specializes in advanced laser technology for ophthalmic procedures, particularly in the realm of vision correction. Their innovative solutions enhance surgical precision and patient outcomes in the treatment of refractive vision errors. IntraLase Corporation, founded in 1997 and headquartered in Irvine, US, develops excimer laser technology for LASIK eye surgeries. The company experienced a significant strategic shift when it was acquired by Abbott Laboratories for USD 808 mn in April 2007, marking a pivotal moment in its history.


This acquisition followed a series of 5 deals that underscored the company's growth trajectory. IntraLase Corporation offers a suite of laser-assisted surgical technologies designed to improve the quality and safety of vision correction procedures. Their flagship product, the IntraLase iFS laser system, provides unparalleled precision in creating corneal flaps, which is crucial for LASIK surgeries. The company serves a global market including North America and Europe, catering to a range of clients from individual surgeons to large ophthalmic practices.


IntraLase Corporation's revenue model primarily consists of sales from its advanced laser systems and ongoing service agreements with clients. Revenue is generated through the sale of equipment, as well as maintenance and support contracts, which ensures a continuous revenue stream. Following its acquisition by Abbott Laboratories, IntraLase Corporation is aligned with Abbott's strategic vision for expanding into new markets. The company plans to enhance its product offerings with the development of next-generation laser systems aimed at improving surgical outcomes.


The funding from the acquisition will support research and development initiatives, thereby facilitating the launch of innovative products in the ophthalmic market by 2025.


Current Investors

Meritech Capital Partners, Brentwood Venture Capital, EDF Ventures

Primary Industry

Medical Devices & Equipment

Sub Industries

Optometrists & Opticians Products and Services, Medical Devices & Equipment

Website

www.intralasefacts.com

Verticals

HealthTech

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.